| Factor Information | |
|---|---|
| Data ID | 1253 |
| Factor | miR-19a level |
| Description | The levels of miR-19a were significantly increased in the PAH samples. The value of the area under the receiver-operating characteristic curve was 0.781 (95% confidence interval, CI = 0.612–0.950, P\0.0001) for the miR-19a assay. |
| Biomarker | YES |
| Classification | D4 (molecular factor - RNA) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH |
| p Value | <0.0001 |
| OR | 0.781 |
| Conclusion | Circulating miR-19a turned out to be a pronounced marker for PAH. Our observations suggest that miR-19a expression is enhanced in PAH blood. Circulating miR-19a may be a novel biomarker for the diagnosis of PAH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 91 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD |
| Reference | |
|---|---|
| PMID | 27837306 |
| Year | 2016 |
| Title | Circulating microRNA as a Novel Biomarker for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | Blood samples and lung tissues | |
| Region | Beijing, China | |
| Method | miRNA arrays, real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | mPAP>45mmHg, patients with severe PAH due to VSD, PAH group)(Treatment) | mPAP＜25 mmHg , patients with VSD but non-PAH, control group(Control) |
| Number | 14 | 16 |
| Age | 4.0 ± 1.2 years | 3.8 ± 0.9 years |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | N/A | N/A |
